Search methods, page 6, line 38: "Full search strategy is presented in supplementary Appendix 1."
The journals / conference proceeding searched (as mentioned in the PROSPERO record) could also be mentioned in this appendix?
Types of interventions, page 7: The authors list different types of antacids compared to placebo or standard care. Did the authors not have any interest in comparing the different types of antacids to each other? I also note that the PROSPERO record also says nonpharmacological interventions were a comparator intervention. Are the 'Types of Interventions' listed in the manuscript a change from the protocol record, or is it just that no trials of non-pharmacological interventions were found?
Primary outcome (page 8): Please add the reference to the reflux index score which is used in the PROSPERO record. I suggest also listing some of the clinical symptoms as listed in PROSPERO.
There are no statistical methods mentioned at all within this paper. I note that there is a sentence within the discussion: "The heterogeneity of the interventions precluded a meta-analysis."
This should be within the methods section before the results, as well as information on how the amount of heterogeneity was judged (and how the amount was judged to be too high for meta-analysis) as well as details of the actual approach taken -i.e. a narrative description of results as reported in the original publications. I also note that the authors call their analysis a 'qualitative analysis' within their title. This is not technically correct, qualitative analyses involve analysis of themes, free text etc. -what the authors have done here is a narrative analysis.
Effects of interventions: For clarity, please start each of the subsections, start off by stating how many studies / how many participants inform each comparison It is not clear in Table 2 and 3 exactly what all of the measures aree.g. means, ranges, percentages etc. Please add some further description within the tables or in footnotes to the tables. It would also be helpful to have the number of patients that the results apply to within the tables.
Please also be consistent when referring to the results of different comparisons -e.g. for Sodium Alginate (Gaviscon) vs Placebo, only the statistically significant results are summarised, whereas for other comparisons both significant and non-significant results are reported.
I suggest giving a brief summary of all results, whether statistically significant or not.
Discussion: minor point, the authors have a heading on page 15 titled 'Summary of main results' -I think that all of the discussion text above this heading also belongs in this section. "Corvaglia (b) et al and Corvaglia (a) et al did not report any form of random sequence generation for allocation." -Not reporting details should be 'unclear' risk of bias rather than 'high.' I assume that these studies were at least described as randomised?
Appendix 4: Cochrane Summary of Findings tables (GRADE tables) must follow a certain format. I appreciate that this is not a Cochrane Review, but I suggest that following the guidance as closely as possible will produce the most informative tables. Specifically It is recommended to produce a separate table for each comparison (e.g. Alginate vs placebo, Proton pump inhibitors vs placebo) and summarise the important outcomes in all tables, even if there is no data for the outcome (for example, it is an important finding that there is no adverse event data for an intervention). So I suggest producing three separate tables, each with Improvement and Symptom Score and Adverse events in them, estimates of illustrative risk and relative effect where possible and a separate GRADE judgement for each outcome in each table.
Also, reasons should be given for downgrading to 'Very Low' quality of evidence -"Weak" evidence is not one of the terms used in GRADE terminology. 
GENERAL COMMENTS
This systematic review (SR) on antacid treatment for GER included controlled studies on H2 blockers, proton pump inhibitors and alginates and identified 6 studies meeting inclusion criteria (4 with cross-over design). Studies were rather heterogeneous, so that they could not perform a proper meta-analysis on them. They found that omeprazol decreased esophageal acid exposure time, while sodium alginate decreased reflux symptoms. They conclude that there is insufficient evidence to recommend antacid therapy for the treatment of GER.
This is a well-written SR, yet I do not consider it properly systematic or complete: If studies on alginates are included, then studies on feed thickeners should be included as well, as both share similar a mechanism of action: they reduce esophageal acid exposure time. Thus, it seems somewhat arbitrary to include one (alginates), but exclude the other (feed thickeners), although prospective controlled studies are available on the latter (e.g. Wenzl et al., Pediatrics 2003). Otherwise, the authors have followed up-to-date guidelines for performing systematic reviews, so that I have no minor comments to offer. 
REVIEWER

GENERAL COMMENTS
The aim of this systematic review was to assess evidence on the effects of antiacid drugs for the management of gastroesophageal reflux in preterm infants. This is an interesting topic especially since antiacids are very often prescribed in neonatal units. However, the review methodology and findings are very poorly reported and the conclusions are not in line with the uncertainties of the main findings. Also, it is regretful that authors do not discuss and put forward the heterogeneity in the design of clinical trials evaluating antiacids in the preterm infants specifically the choice of study endpoints that varied widely and precluded the possibility of a meta-analysis. Globally, the manuscript is poorly written.
Comments by section BACKGROUND 1. I would suggest that authors do not refer to antacids merely as 'interventions' or use the term 'pharmacology therapy' but as 'pharmacological therapy or drug interventions'. 2. Please define all abbreviations when mentioned for the first time throughout the manuscript for example NEC, line 25 not defined. GORD is gastroesophageal reflux disease but is never defined either in the text. Usually meta-analysis of randomised controlled trials provides elements on drug efficacy. Please harmonise throughout the manuscript accordingly. METHODS 1. Please edit your manuscript that includes titles both in majuscules and minuscules.
2. Appendix 1: your full search strategy is not comprehensible.
-Are there already 3 Cochrane reviews on the subject? Please comment… -Pubmed: search yielded a total of 4195 publications and then every new search begins by a number in bold letters which corresponds to what? Did they combine all these searches? That is not a 'typical' way to search an electronic database.
3. Line 5, page 7: please rephrase the sentence because you actually included all randomised controlled trials evaluating antacids or you have considered for your study all available antiacid drug therapies.
4. How was the selection of articles by 'paired reviewers' performed practically? It would be interesting to know given the important number of articles to select (> 20.000) and the short time between the end of the review and the article submission. In addition, these details are required in the PRISMA guidelines.
5. Line 37, page 7: '…further information was obtained from study authors'. Figure 1 should follow PRISMA recommendations. Importantly, authors do not provide: 1) the details of articles identified from each source, 2) any details about reasons for article exclusions and 3) in the text it is mentioned that 18881 were excluded whereas in Figure  1 , after removing duplicates there were only 1230 articles left. Please correct this information. 2. Table 1 has to be entirely re-structured as information is presented in a rather 'chaotic' way: -For example, authors give information on the comparison to a placebo for the first 3 RCTs in the 'methods' line but for the remaining 3, a placebo is mentioned in the 'Interventions' line of the table. Same for blinding, definitions of the study population, frequency of drug administration etc… it is provided for some publications but not for all or not in the same line of table.
-A separate line for 'diagnostic symptoms' should be considered -Use the term 'blinded' or 'masked study' but not both inconsistently.
-For Corvaglia (b), alginate was given just once after a meal? It is mentioned later (discussion) that it was given twice… -For Orenstein et al, it is mentioned that placebo was administered identically but without active drug' (?!) what does that mean? Not clear at all… -For Wheatley et al., it is mentioned that interventions were provided 'with saline placebo' (?!). again not clear at all on the methodology… was there a double dummy involved? -Where are characteristics such as study duration, period of followup, number of patients lost to follow-up provided in the manuscript? Authors give some partial information in the discussion section but this is not at all appropriate.
-Authors should describe primary and secondary RCTs' outcomes separately.
3. Line 23, page 10: authors mention 'Primary outcome' but they actually describe inclusion criteria. Please correct. 4. Shouldn't primary and secondary outcome be described in the paragraph 'effects of interventions'? 5. Lines 6-7, page 11: mentioned abbreviations (ph-GORs, aMIIGORs etc..) are not defined in the text but only on the footnote of Table 2 . This is not an appropriate way to present results. 6. In general, the paragraph 'effects of interventions" is very difficult to read. Authors should consider moving Appendix 5 to the main manuscript. Presentations of results lacks synthesis and individual study findings as reported in a way that is very difficult to comprehend. 7. Table 2 . Units are lacking in the columns and 'P' is actually the pvalue provided by the original publication (no details given). More precisions should be provided. 8. Table 3 .
-Units should be given in the columns. Actually there are only provided for the total number of GORD signs and symptoms.
-How was the 'responder rate' defined in the Orenstein publication? 9. Line 11, page 13: authors provide for the first time in the manuscript the test used in the publication to compare treatment groups. This should be either deleted or given for all 'p' values provided. DISCUSSION 1. Line 45, page 13: '…review demonstrates the lack of efficacy and safety data for anti-GORD drug therapy in preterm infants'. This is not supported by evidence because the review just demonstrated that there is no evidence to support this and draw reliable conclusions. In addition, the only drugs that were evaluated in the review were antiacids, not all anti-GORD drugs. Please rectify.
2. There is a lot of information about the findings of RCTs included in the review that are provided in the discussion when they should have been mentioned in the results section. Some examples: -Line 2, page 14: authors mention that sodium alginate didn't reduce the total number of apnoea of prematurity nor GOR-related apnoeas. This information should be in the results section.
-Lines 43 to 48: findings about serious adverse events and patients lost to follow-up that should be moved to the results section. 5. As mentioned previously, authors use in the discussion the terms 'efficacy' and 'effectiveness' in an equivalent way although these two notions are completely different. They should rectify the entire manuscript according to their primary objective.
Due to difficulties in conducting manual searches we haven't completed the search of studies in these platforms.
Comment: Types of interventions, page 7: The authors list different types of antacids compared to placebo or standard care. Did the authors not have any interest in comparing the different types of antacids to each other?
Response: As described in the protocol (registered with PROSPERO) the interventions to consider were different types of antacids compared to placebo or non-pharmacological interventions/ standard care. We did not set out to compare the different antacids to each other.
Comment: I also note that the PROSPERO record also says non-pharmacological interventions were a comparator intervention. Are the 'Types of Interventions' listed in the manuscript a change from the protocol record, or is it just that no trials of non-pharmacological interventions were found?
Response Comment: There are no statistical methods mentioned at all within this paper. I note that there is a sentence within the discussion: "The heterogeneity of the interventions precluded a meta-analysis."
This should be within the methods section before the results, as well as information on how the amount of heterogeneity was judged (and how the amount was judged to be too high for metaanalysis) as well as details of the actual approach taken -i.e. a narrative description of results as reported in the original publications. Response: We have removed ''qualitative analysis' from the title and specified in the Statistical analysis paragraph that this is a narrative review.
Comment: Effects of interventions: For clarity, please start each of the subsections, start off by stating how many studies / how many participants inform each comparison
Response: We have modified the 'Effects of intervention' section as suggested.
Comment: It is not clear in Table 2 and 3 exactly what all of the measures are -e.g. means, ranges, percentages etc. Please add some further description within the tables or in footnotes to the tables. It would also be helpful to have the number of patients that the results apply to within the tables. Appendix 4: Cochrane Summary of Findings tables (GRADE tables) must follow a certain format. I appreciate that this is not a Cochrane Review, but I suggest that following the guidance as closely as possible will produce the most informative tables.
Specifically It is recommended to produce a separate table for each comparison (e.g. Alginate vs placebo, Proton pump inhibitors vs placebo) and summarise the important outcomes in all tables, even if there is no data for the outcome (for example, it is an important finding that there is no adverse event data for an intervention).
So I suggest producing three separate tables, each with Improvement and Symptom Score and Adverse events in them, estimates of illustrative risk and relative effect where possible and a separate GRADE judgement for each outcome in each table.
Also, reasons should be given for downgrading to 'Very Low' quality of evidence -"Weak" evidence is not one of the terms used in GRADE terminology.
Response: We have summarised the important outcomes in 3 SOF tables. (Appendix 4)
Reviewer: 2
Thank you for your valued feedback and suggestions on this review.
Comments to the Author
This systematic review (SR) on antacid treatment for GER included controlled studies on H2 blockers, proton pump inhibitors and alginates and identified 6 studies meeting inclusion criteria (4 with crossover design). Studies were rather heterogeneous, so that they could not perform a proper metaanalysis on them.
They found that omeprazol decreased esophageal acid exposure time, while sodium alginate decreased reflux symptoms. They conclude that there is insufficient evidence to recommend antacid therapy for the treatment of GER.
This is a well-written SR, yet I do not consider it properly systematic or complete: If studies on alginates are included, then studies on feed thickeners should be included as well, as both share similar a mechanism of action: they reduce esophageal acid exposure time. Thus, it seems somewhat arbitrary to include one (alginates), but exclude the other (feed thickeners), although prospective controlled studies are available on the latter (e.g. Wenzl et al., Pediatrics 2003).
Response: The alginate preparation included in our review contains both sodium alginate and sodium bicarbonate (Gaviscon Reckitt Benckiser Healthcare, Hull, UK ). The two substances contained in the formulation seem to work together as thickening and acid buffering factors. A separate systematic review on use of feed thickeners for management for GOR has previously been conducted. Comment: Otherwise, the authors have followed up-to-date guidelines for performing systematic reviews, so that I have no minor comments to offer.
Reviewer: 3
Thank you for your comments suggesting improvements and additions to our review.
Comments by section BACKGROUND 1. I would suggest that authors do not refer to antacids merely as 'interventions' or use the term 'pharmacology therapy' but as 'pharmacological therapy or drug interventions'.
Response: We have used the term 'pharmacological therapy' in the revised manuscript.
2. Please define all abbreviations when mentioned for the first time throughout the manuscript for example NEC, line 25 not defined. GORD is gastroesophageal reflux disease but is never defined either in the text.
Response: We have defined each abbreviation on first use.
